Endocrine Abstracts

In Europe, rhPTH(1-84) is an approved adjunctive treatment for adults with chronic hypoparathyroidism that cannot be adequately controlled with conventional therapy. Here we present data from the longest rhPTH(1-84)-treated study cohort of patients with hypoparathyroidism. In a single-centre, single-arm, phase 4 study (NCT02910466), long-term rhPTH(1-84) treatment (25, 50, 75, or 100 μg/day subcutaneously) was evaluated in adults with chronic hypoparathyroidism who mainta...